Will you be covering pharma? if so holler and happy to help you making connections in Basel.

Wait till you see how much revenues will lose exclusivity from the GLP-1 class (starting in the early ‘30s)….
Also: what matters is how much those drugs will be selling just before they lose excl., not how much they sold in 2023…

Anything MORE than that is tough for very different reasons, mainly IMHO because team tends 2 gravitate 2wards larger average investments (hard to make > time in ur day). & historically that pigeon holes u in a very specific set of companies which correlate w/ public market bubbles (IPOs)…

Depending on strategy, anything b/w 300-750m is ok, depending on:
how often u want to fundraise;
how many companies (and therefore senior partners) u have / fund;
how much incubation vs series A/B u do.
Anything less is very tough (subscale, can’t pay talent to join, can’t follow ur investments).

Ah, yes: the dirty little secret of our industry… humans are an insanely complex and non-deterministic set of overlapping and pleiotropic molecular interactions…
can somebody explain that to the tech folks who want to “disrupt” drug dev? @dereklowe.bsky.social should opine 😉

Pleiotropic interactions with other cell proteins am guessing?

So, still (likely) one of the best years out of the last 10?

Not to sound like a colossal pedant, but I’d like to note we barely started Dec and there is a bit of a seasonal pattern to M&A being back-loaded.
So, don’t bet money on it, but my guess is that 2024 will end up between 37 (bare minimum, just adding the one month missing) and 40+.

I hear Cloud 9 in Aspen is not entirely dissimilar (though it seems they spray each other with Champagne ???)

That looks amazing!

You should have come to say hi!!!